CDMO collaboration through the capital and business alliance with TEIJIN LIMITED and the tender offer
First written in FY2021-Q3. 9 of 13 entries say "Advanced", first in FY2022-Q2. Latest entry: 2026-06-19.
No other company in this theme has enough history to compare yet.
- FY2026-H1RaisedAnnual report
「In July 2025, our joint project with Teijin Regenerative Medicine Co., Ltd. was selected for the Ministry of Economy, Trade and Industry's regenerative medicine CDMO subsidy program. Through investment on the scale of several billion yen, we will expand facilities and equipment and develop human resources, aiming to increase the number of regenerative medicine product contracts from Japan and overseas.」
The CDMO collaboration with the TEIJIN Group expanded into a plan involving the award of subsidies, facility and equipment investment on the scale of several billion yen, human resources development, and an increase in orders received in Japan and overseas. - FY2025-H1AdvancedAnnual report
「As part of its co-creation initiatives with TEIJIN LIMITED, the company will strengthen activities to create further business opportunities, including jointly exhibiting at trade shows with 帝人リジェネット株式会社.」
Regarding its CDMO collaboration with the TEIJIN Group, the company indicated a policy of strengthening concrete co-creation activities aimed at developing customers and projects, including jointly exhibiting at trade shows with 帝人リジェネット株式会社. - FY2024AdvancedAnnual report
「Agreement title Basic Outsourcing Agreement under the License Agreement Counterparty 帝人リジェネット株式会社 Date of agreement 19 March 2024 Contract term From 1 April 2024 through 31 March 2025.」
The CDMO collaboration with TEIJIN LIMITED took concrete form through a technical guidance outsourcing agreement with 帝人リジェネット株式会社, established in August 2023, effective from April 2024. - FY2024-Q2AdvancedAnnual report
「On 1 August 2023, TEIJIN LIMITED established 帝人リジェネット株式会社, a company dedicated to the regenerative medicine CDMO business. The company will collaborate with 帝人リジェネット株式会社 as part of the TEIJIN Group to expand the CDMO business.」
The CDMO collaboration with TEIJIN LIMITED took concrete form through the establishment of 帝人リジェネット株式会社 and the creation of a framework for collaboration with that company as part of the TEIJIN Group. - FY2024-Q1RaisedAnnual report
「The company also entered into a memorandum of agreement on an international strategic business alliance for a contract development and manufacturing organization (CDMO) business in regenerative medicine with TEIJIN LIMITED and Resilience US, Inc., a biotechnology venture based primarily in the United States and expanding globally, headquartered in California, United States, effective 21 April 2023. Going forward, the 3 companies will establish a cooperative framework for the regenerative medicine CDMO business based on the business alliance.」
The company agreed to expand its CDMO collaboration with TEIJIN LIMITED into an international 3-party cooperative framework with the addition of Resilience US, Inc., which operates primarily in the United States. - FY2023-Q3AdvancedAnnual report
「Although orders received from the parent company, TEIJIN LIMITED (hereinafter, “TEIJIN”), increased, overall sales declined year on year because a contract signing fee had been recognized in the previous fiscal year.」
Following the capital and business alliance with TEIJIN LIMITED, the company disclosed concrete progress in the business alliance in the form of increased orders received from TEIJIN LIMITED. Meanwhile, total sales from the contract business declined because of the反動 from recognition of a contract signing fee in the previous year. - FY2023-Q2AdvancedAnnual report
「The company also announced that, effective 27 September 2022, it would jointly establish a “Regenerative Medicine Platform” in Kashiwanoha Smart City (Kashiwa, Chiba Prefecture) with TEIJIN LIMITED, the National Cancer Center, and Mitsui Fudosan Co.,Ltd. The platform will provide a one-stop process spanning research and development of regenerative medicine products, business planning and commercial production.」
The capital and business alliance with TEIJIN LIMITED was given concrete form through the establishment of a regenerative medicine platform in Kashiwanoha Smart City with the addition of the National Cancer Center and Mitsui Fudosan Co.,Ltd. - FY2023-Q1AdvancedAnnual report
「Although orders received from the parent company, TEIJIN LIMITED (hereinafter, “TEIJIN”), increased, overall sales declined year on year because a contract signing fee had been recognized in the previous fiscal year.」
Following the capital and business alliance with TEIJIN LIMITED, the company disclosed concrete progress in the business alliance in the form of increased orders received from TEIJIN LIMITED. - FY2022AdvancedAnnual report
「Agreement title Basic Outsourcing Agreement Counterparty TEIJIN LIMITED Date of agreement 31 March 2022 Contract term From 1 April 2022 through 31 March 2023. However, if neither party requests an amendment or non-renewal of this agreement by 2 months before the expiration date, the agreement will be renewed for an additional 1 year on the same terms, and likewise thereafter. Principal terms The company will undertake work associated with the launch of TEIJIN LIMITED's new business related to regenerative medicine, using the company's technologies and know-how.」
The capital and business alliance with TEIJIN LIMITED was given concrete form through the renewal of a basic outsourcing agreement related to the launch of a new regenerative medicine business. - FY2022-Q2AdvancedAnnual report
「TEIJIN LIMITED 23,439,173 57.71」
The company disclosed that, as of 30 September 2021, TEIJIN LIMITED held 23,439,173 shares, representing 57.71% of issued shares. - FY2021-Q3First statedAnnual report
「Matters concerning the tender offer: ① Tender offer period: 20 business days from 1 February 2021 (the "Commencement Date"). ② Purchase price: ¥820 per common share. Matters concerning the Capital and Business Alliance Agreement: ① Purpose: The Tender Offeror and the Company aim to realize substantive synergies between the two parties and enhance their corporate value through a capital and business alliance. Under the business alliance, after the tender offer is completed, the Tender Offeror will, itself and through its subsidiaries, provide, as part of the business alliance under the Capital and Business Alliance Agreement, (i) expertise, know-how and resources that contribute to the Company's business and (ii) infrastructure necessary for the Company's business operations. After the tender offer is completed, the Company will, while giving due consideration to conflicts of interest between the Tender Offeror and the Company's minority shareholders, provide expertise and know-how that contribute to launching the Tender Offeror's CDMO business and collaborate in that CDMO business. The details of this business alliance will be discussed in good faith going forward.」
On 29 January 2021, the company resolved to issue a favorable opinion on TEIJIN LIMITED's tender offer and to enter into a capital and business alliance agreement. The company plans to remain listed after the tender offer and to receive business expertise, know-how, resources and infrastructure from TEIJIN LIMITED, while collaborating with TEIJIN LIMITED on launching its CDMO business.